Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study.
Kyaw Zin TheinDaniel D KarpApostolia TsimberidouJing GongSelma SulovicJatin ShahDenái R MiltonDavid S HongFilip JankuLacey McQuinnBettzy A StephenRivka ColenBrett W CarterTimothy A YapSarina A Piha-PaulSiqing FuFunda Meric-BernstamAung NaingPublished in: Investigational new drugs (2021)
The RP2D of selinexor was 60 mg QW in combination with CT. The combination conferred viable clinical activity with durable objective responses which should further be explored in tumor types for which CT is used as standard of care. Trial information. ClinicalTrials.gov Identifier: NCT02419495. Sponsor(s): Karyopharm Therapeutics. (Trial registration: NCT02419495. Registered 14 April 2015, https://clinicaltrials.gov/ct2/show/NCT02419495 ).